In short
A new clinical trial is underway to investigate the potential of Exidavnemab, a promising drug for Parkinson's Disease (PD) treatment. This Phase 2a study aims to assess the safety, tolerability, and pharmacokinetics of Exidavnemab in patients with mild to moderate Parkinson's Disease who are on stable symptomatic medication. The trial will provide valuable insights into the drug's effectiveness and help determine appropriate dosing for future studies.
At a glance
- Study Type
- Phase 2a, randomized, double-blind, placebo-controlled
- Participants
- Patients with mild to moderate Parkinson's Disease on stable medication
- Intervention
- Exidavnemab administered via intravenous infusion
- Dosing
- Two dose cohorts vs placebo (2:1 ratio)
- Primary Outcome
- Safety and tolerability assessment
- Secondary Outcomes
- Pharmacokinetics, dose range establishment, immunogenicity assessment
- Duration
- 176 days from first dose
- Total Participants
- Approximately 24
What is Exidavnemab?
Exidavnemab is a new investigational drug being studied for the treatment of Parkinson's disease. Parkinson's disease is a progressive nervous system disorder that affects movement, often causing tremors, stiffness, and difficulty with balance and coordination. This drug is currently undergoing clinical trials to evaluate its potential benefits for patients with mild to moderate Parkinson's disease who are already on stable symptomatic medication.
Purpose of the Study
The main goal of the current study is to assess the safety and tolerability of exidavnemab when given in multiple doses, compared to a placebo. A placebo is a substance that looks like the real drug but contains no active ingredients. This comparison helps researchers understand if any side effects are truly caused by the drug itself.
Study Design
The study is designed as a Phase 2a clinical trial, which means it's an early stage of testing the drug in humans. Here are some key features of the study design:
- Randomized: Participants are randomly assigned to either receive exidavnemab or a placebo. This helps reduce bias in the results.
- Double-blind: Neither the participants nor the researchers know who is receiving the real drug or the placebo. This further reduces potential bias.
- Placebo-controlled: Some participants receive a placebo instead of the active drug, allowing for comparison.
- Multiple ascending dose (MAD): The study will test different dose levels of exidavnemab to find the most appropriate dose.
The trial will include two dose cohorts, with participants in each cohort randomly allocated in a 2:1 ratio to receive either exidavnemab or placebo. This means that for every three participants, two will receive the drug and one will receive the placebo.
How is Exidavnemab Administered?
Exidavnemab is administered as an intravenous (IV) infusion. This means the drug is given directly into a vein, allowing it to enter the bloodstream quickly. The placebo is also given as an IV infusion to maintain the double-blind nature of the study.
Safety and Side Effects
A primary focus of this study is to evaluate the safety of exidavnemab. Researchers will be closely monitoring:
- Adverse events (AEs): Any unfavorable and unintended sign, symptom, or disease that occurs during the study, whether or not it's related to the drug.
- Serious adverse events (SAEs): AEs that result in hospitalization, disability, or are life-threatening.
- Withdrawals due to AEs: Cases where participants need to stop taking the drug due to side effects.
These safety measures will be monitored from the first dose until 176 days after starting the treatment.
Pharmacokinetics
The study will also look at the pharmacokinetics of exidavnemab. Pharmacokinetics refers to how the body processes a drug, including how it's absorbed, distributed, metabolized, and excreted. Specifically, researchers will measure the area under the serum concentration-time curve (AUC), which shows how much of the drug is in the bloodstream over time. This information helps determine the appropriate dosing for the drug.
Immunogenicity
Another aspect of the study is to assess the immunogenicity of exidavnemab. Immunogenicity refers to the ability of a substance to provoke an immune response in the body. Researchers will be looking for the development of:
- Anti-drug antibodies (ADAs): Antibodies that the body might produce against exidavnemab.
- Neutralizing antibodies (NAbs): A specific type of ADA that could potentially reduce the effectiveness of the drug.
This information is crucial for understanding how the body might react to long-term use of the drug.
Future Implications
The results of this study will help researchers determine:
- The appropriate dose range for future, larger studies (known as proof-of-concept trials).
- The safety profile of exidavnemab in patients with Parkinson's disease.
- How the body processes and responds to the drug.
If exidavnemab shows promising results in terms of safety and tolerability, it may progress to larger clinical trials to further evaluate its effectiveness in treating Parkinson's disease.